Managing Dyslipidemia for PCPs

CE / CME

Optimizing Cardiovascular Health: Attaining LDL-C Targets Through Comprehensive Therapeutic Approaches—A Primary Care Update

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: August 21, 2024

Expiration: August 20, 2027

Activity

Progress
1 2
Course Completed

References

  1. Centers for Disease Control and Prevention. Heart disease facts. cdc.gov/heart-disease/data-research/facts-stats/index.html. Accessed August 1, 2024.
  2. American Heart Association. Population shifts, risk factors may triple U.S. cardiovascular disease costs by 2050. newsroom.heart.org/news/population-shifts-risk-factors-may-triple-u-s-cardiovascular-disease-costs-by-2050#:~:text=Cardiovascular%20disease%2C%20including%20stroke%2C%20(,more%20than%20180%20million%20people. Accessed August 1, 2024.
  3. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
  4. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459-2472.
  5. Shapiro MD, Bhatt DL. "Cholesterol-years" for ASCVD risk prediction and treatment. J Am Coll Cardiol. 2020;76:1517-1520.
  6. Domanski MJ, Tian X, Wu CO, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol. 2020;76:1507-1516.
  7. Bartels A, O'Donoghue K. Cholesterol in pregnancy: a review of knowns and unknowns. Obstet Med. 2011;4:147-151.
  8. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148:e9-e119.
  9. American Heart Association. The American Heart Association diet and lifestyle recommendations. heart.org/en/healthy-living/healthy-eating/eat-smart/nutrition-basics/aha-diet-and-lifestyle-recommendations. Accessed August 1, 2024.
  10. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. JAMA. 2016;316:1289-1297.
  11. Sadowska A, Osinski P, Roztocka A, et al. Statins-From fungi to pharmacy. Int J Mol Sci. 2023;25.
  12. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
  13. Long-Term Intervention with Pravastatin in Ischaemic Disease Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
  14. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
  15. Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
  16. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
  17. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
  18. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
  19. Hoogeveen RC, Ballantyne CM. Residual cardiovascular risk at low LDL: Remnants, lipoprotein(a), and inflammation. Clin Chem. 2021;67:143-153.
  20. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082-e1143.
  21. Writing Committee, Lloyd-Jones DM, Morris PB, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American College of Cardiology solution set oversight Committee. J Am Coll Cardiol. 2022;80:1366-1418.
  22. Bardolia C, Amin NS, Turgeon J. Emerging non-statin treatment options for lowering low-density lipoprotein cholesterol. Front Cardiovasc Med. 2021;8:789931.
  23. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-2397.
  24. Ezetemibe [prescribing information]. Jersey City, NJ: Organon LLC; 2024.
  25. Alirocumab [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals; 2024.
  26. Evolocumab [prescribing information]. Thousand Oaks, CA: Amgen, Inc; 2024.
  27. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713-1722.
  28. Goodman SG, Steg PG, Poulouin Y, et al. Long-term efficacy, safety, and tolerability of alirocumab in 8242 patients eligible for 3 to 5 years of placebo-controlled observation in the ODYSSEY OUTCOMES trial. J Am Heart Assoc. 2023;12:e029216.
  29. O'Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146:1109-1119.
  30. Agarwala A, Quispe R, Goldberg AC, Michos ED. Bempedoic acid for heterozygous familial hypercholesterolemia: From bench to bedside. Drug Des Devel Ther. 2021;15:1955-1963.
  31. Bempedoic acid [prescribing information]. Ann Arbor, MI: Esperion Therapeutics, Inc.; 2024.
  32. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388:1353-1364.
  33. Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. JAMA. 2023;330:131-140.
  34. Inclisiran [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2024.
  35. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507-1519.
  36. American College of Cardiology. An update on lipoprotein(a): The latest on testing, treatment, and guideline recommendations. acc.org/latest-in-cardiology/articles/2023/09/19/10/54/an-update-on-lipoprotein-a. Accessed August 1, 2024.
  37. Alhomoud IS, Talasaz A, Mehta A, et al. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies. Pharmacotherapy. 2023;43:1051-1063.
  38. Berman AN, Biery DW, Besser SA, et al. Lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2024;83:873-886.
  39. Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2022;16:e77-e95.
  40. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-188.
  41. Tsimikas S, Clopton P, Brilakis ES, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation. 2009;119:1711-1719.
  42. Virani SS, Brautbar A, Davis BC, et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012;125:241-249.
  43. Kar S. Elevated lipoprotein A in South Asians and the associated risk of cardiovascular disease: A systematic review. Curr Probl Cardiol. 2021;46:100581.
  44. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63:470-477.
  45. Clarke R, Von Ende A, Schmidt LE, et al. Apolipoprotein proteomics for residual lipid-related risk in coronary heart disease. Circ Res. 2023;132:452-464.
  46. Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015;386:1472-1483.
  47. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-3337.
  48. American College of Cardiology. ASCVD risk estimator plus. tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/. Accessed August 1, 2024.
  49. Needymeds.org. Medicare information. needymeds.org/medicare-info. Accessed August 1, 2024.
  50. National Association of Free and Charitable Clinics. nafcclinics.org/. Accessed August 1, 2024.
  51. Medicare.gov. Get started with Medicare. medicare.gov/. Accessed August 1, 2024.
  52. American Hospital Association. Addressing social determinants of health presentation. aha.org/landing-page/addressing-social-determinants-health-presentation. Accessed August 1, 2024.